Feasibility study of adjuvant chemotherapy with TS-1 followed by DCS (DTX+CDDP+S-1) for stage III gastric cancer
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-UMIN000012785
- Lead Sponsor
- Shimane University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
(1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal carcinoma, and multicentric cancer. (2) Patients who are contraindicated to S-1, CDDP, and DTX. (3) Patient is taking flucytosine and phenytoin. (4) Patients with the history of severe drug hypersensitivity. (5) Patients with severe complication (intestinal paralysis, intestinal obstruction, interstitial pneumonitis, pulmonary fibrosis, severe diabetes, heart failure, renal failure, liver cirrhosis, liver failure, etc.). (6) Patients with diarrheal disease or watery diarrhea. (7) Pregnant and/or nursing women (8) Patients with positive HBs antigen (9) Any subject judged by the investigator to be unfit for any reason to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment completion rate after 2 cycle of S-1, DTX plus CDDP
- Secondary Outcome Measures
Name Time Method Overall Survival, Relapse Free Survival, Completion rate of S-1 for 1year, Safety